CDCA5 knockdown potentiates olaparib sensitivity in BRCA1-mutated ovarian cancer through autophagy activation.

ABSTRACT:

Background

BRCA1-mutated ovarian cancer poses substantial therapeutic hurdles due to its poor prognosis and resistance to traditional therapies. Although acquired resistance is still a significant obstacle, PARP inhibitors, e.g., olaparib, have demonstrated promise in prolonging progression-free survival (PFS) in these individuals. The therapeutic potential of CDCA5 silencing in conjunction with olaparib to improve treatment effectiveness for ovarian cancer with a BRCA1 mutation is examined in this study.

Methods

Using BRCA1-mutated ovarian cancer cell lines (UWB1.289 and SNU251) and xenograft models, we analyzed the effects of CDCA5 knockdown alone or combined with olaparib. Functional assays (CCK-8, immunofluorescence, TEM, western blot) evaluated proliferation, autophagy,

SUBMITTER: Wu W 

PROVIDER: S-EPMC12484512 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature